Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




New Pathogen Detection Assay Pairs Molecular Inversion Probes, Next-Generation Sequencing

By LabMedica International staff writers
Posted on 21 Feb 2022

Next-generation sequencing is rapidly finding footholds in numerous microbiological fields, including infectious disease diagnostics. Molecular inversion probe (MIP) technology can be coupled with next-generation sequencing (NGS) for targeted, multiplexed pathogen detection.

Application of molecular inversion probes (MIPs) before sequencing mitigates several of the classic issues surrounding NGS. Issues such as cost per sample, host background, and necessity for a priori knowledge for real-time PCR are mitigated through MIP multiplex amplification of several signatures at once to include virulence elements, resistance genes, and other identifying elements.

Infectious Disease specialists at the Army Medical Research Institute of Infectious Disease (Fort Detrick, MD, USA) designed a pathogen detection panel consisting of 94 probes targeting 17 viral pathogens and one parasitic organism, eight probes targeting variable 16S rRNA gene regions for bacterial taxonomic classification, as well as 71 probes targeting antibiotic resistance elements. Human clinical serum samples from suspected chikungunya virus (CHIKV) infections were analyzed and determined by using real-time RT-PCR

The Pathogen Identification Panel (PIP) was designed by using the CLC Genomics Workbench (CLC Bio, Cambridge, MA, USA) and AlleleID 7.73 (PREMIER Biosoft, Palo Alto, CA, USA). The scientists tested the ability of the MiSeq sequencer (Illumina, San Diego, CA, USA) and the MinIon sequencer (Oxford Nanopore Technologies [ONT], Oxford Science Park, UK) to sequence small amplicons originating from this panel for the identification of pathogens in complex matrices.

The investigators reported that Illumina sequencing did produce more reads than nanopore sequencing; the average number of reads per sample was approximately 500,000 for Illumina and 50,000 for ONT. Nevertheless, in the end, both platforms performed relatively similar in their sensitivity, specificity, and general statistics. The team did discover some nuances between the two platforms, specifically when it came to 16S taxonomic classification. Of the 31 bacterial pathogens targeted with the MIP panel and subsequently sequenced, the team found Illumina sequencing achieved a genus-level concordance of 96.7% compared to 90.3% with nanopore sequencing. While both sequencing platforms misclassified Klebsiella oxytoca as Enterobacter, nanopore sequencing also misclassified Burkholderia cepecia and Enterobacter aerogenes.

Timothy Minogue, PhD, deputy division chief of USAMRIID’s diagnostic systems division and senior author of the study, said, “The main advantage of using MIPs is the ability to multiplex. Compared with multiplex PCR, which requires different sets of primers for different target organisms, MIP enrichment uses universal primers for all amplifications, removing the PCR competition.”

The authors concluded that MIPs continue to be a valuable upfront molecular amplification technique easily adapted to ever-evolving downstream molecular technologies. The fundamental molecular aspects of MIPs, including the specificity and adaptability afforded by the linker backbone, promises this molecular technique will continue to be utilized well into the future. The study was published on January 24, 2022 in The Journal of Molecular Diagnostics.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.